相关实验视频
Updated: Jul 5, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.5K
贝纳利祖马布用于聚炎的eosinophilic granulomatosis:一个回顾性,多中心的队列研究
Alessandra Bettiol1, Maria Letizia Urban1, Roberto Padoan2
1Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy.
The Lancet. Rheumatology
|January 22, 2024
概括
在一项欧洲实践研究中,本拉利祖马布在治疗聚炎 (EGPA) 带来的埃索诺菲尔颗粒瘤症方面表现有前途,该疗法显著改善了疾病活性,并减少了皮质类固醇的使用. 对于具有较高疾病活性的患者,需要进行进一步的试验.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 带有多炎 (EGPA) 的异性粒状炎是一种罕见的全身性血管炎.
- 干白素-5 (IL-5) 抑制剂正在成为EGPA的向疗法.
- 本拉利祖马布向IL-5受体,提供了一种新的治疗方法.
研究的目的:
- 评估本拉利祖马布在EGPA患者的欧洲队列中的实际有效性和安全性.
- 评估治疗反应率,疾病活性和葡萄糖皮质激素剂量.
- 在12个月的时间内分析安全结果和停止治疗.
主要方法:
- 在28个欧洲中心进行了回顾性队列研究.
- 包括121名用本拉利祖马布治疗的复发性耐药EGPA患者.
- 在3,6个月和12个月评估完整响应 (BVAS=0,普雷尼松≤4毫克/天) 和部分响应 (BVAS=0,普雷尼松>4毫克/天).
主要成果:
- 在12个月后,完全响应率达到46.4%.
- 伯明翰血管炎活动评分 (BVAS) 与基线相比显著下降.
- 口服普得尼松剂量在第3个月减少 (p<0.01) 并且在第12个月进一步减少 (p<0.0001).
- 16%的患者报告了不良事件,导致13%的患者停止治疗.
结论:
- 本拉利祖马布在现实临床环境中证明了在管理EGPA方面的潜在有效性.
- 该药物有助于减少疾病活动和降低对皮质类固醇的依赖.
- 需要进一步的研究来证实在基线较高的疾病活性患者中的疗效.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
299
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
299
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
01:19Antiasthma Drugs: Leukotriene Modifiers
302
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
302
01:17Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
01:29Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142